Search

Your search keyword '"Brian J. Ball"' showing total 19 results
Start Over Author "Brian J. Ball"
19 results on '"Brian J. Ball"'

1. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Author

Antoine N. Saliba, Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark R. Litzow, Tara L. Lin, Brian J. Ball, Michael M. Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison Walker, Vu H. Duong, Tibor Kovacsovics, Robert H. Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Kevin L. Peterson, Paula A. Schneider, Molly Martycz, Theophilus J. Gana, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Alice S. Mims, Uma Borate, Amy Burd, Brian J. Druker, Ross L. Levine, John C. Byrd, and James M. Foran

Subjects
Hematology
Published
2023
Full Text
View/download PDF

2. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

Author

Jan Philipp Bewersdorf, Rory M. Shallis, Andriy Derkach, Aaron D. Goldberg, Anthony Stein, Eytan M. Stein, Guido Marcucci, Amer M. Zeidan, Shai Shimony, Daniel J. DeAngelo, Richard M. Stone, Ibrahim Aldoss, Brian J. Ball, and Maximilian Stahl

Subjects
Cancer Research, Oncology, Hematology
Abstract

FLT3, IDH1 and IDH2 inhibitors as well as venetoclax in combination with hypomethylating agents or low-dose cytarabine have expanded treatment options for patients with acute myeloid leukemia (AML). However, little data exist on the efficacy of venetoclax-based therapies in AML patients previously treated with FLT3 or IDH1/2 inhibitors. In this multicenter, retrospective cohort study, we included 44 patients who received venetoclax-based therapy after FLT3, IDH1 or IDH2 inhibitors. The overall response rate (ORR; composite of complete remission [CR]/CR with incomplete count recovery, partial remission, and morphologic leukemia free state) was 56.8% (18.2% CR) and a median overall survival of 9.2 months. While 6 out of 7 patients with

Published
2022
Full Text
View/download PDF

3. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Author

Brian J. Ball, Shukaib Arslan, Paul Koller, Dat Ngo, Michelle Afkhami, Amandeep Salhotra, Monzr Al-Malki, Ahmed Aribi, Haris Ali, Karamjeet Sandhu, Salman Otoukesh, Idoroenyi Amanam, Hoda Pourhassan, Andrew Artz, Peter Curtin, Anthony Stein, Ryotaro Nakamura, Guido Marcucci, Eileen Smith, Vinod Pullarkat, and Ibrahim Aldoss

Subjects
Leukemia, Myeloid, Acute, Sulfonamides, Cancer Research, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Hematology, Bridged Bicyclo Compounds, Heterocyclic
Published
2022
Full Text
View/download PDF

4. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia

Author

Brian J, Ball, Paul B, Koller, and Vinod, Pullarkat

Subjects
Adult, Leukemia, Myeloid, Acute, Sulfonamides, Cancer Research, Oncology, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Humans, Nucleosides, Bridged Bicyclo Compounds, Heterocyclic, Aged
Abstract

Venetoclax in combination with nucleoside analogs such as hypomethylating agents (HMA) and low-dose cytarabine (LDAC) has led to unprecedented response and survival outcomes in patients with acute myeloid leukemia (AML). This has spurred the development of regimens combining venetoclax with other nucleoside analogs with distinct mechanisms of action. Here, we review older and newer nucleoside analogs, the rationale for their combination with venetoclax, and clinical evidence for the combination when available.Venetoclax with HMA prolonged survival in a phase 3 study. Additionally, biologic correlates of response and resistance to venetoclax with HMA have been identified. The addition of venetoclax to standard intensive regimens containing higher doses of cytarabine and purine nucleoside analogs are safe and induce very high rates of remission and measurable residual disease negativity (MRD) negativity in newly diagnosed and relapsed/refractory AML. Investigational nucleoside analogs aim to improve upon the safety, bioavailability, or efficacy of approved venetoclax combinations and are currently being evaluated in clinical studies.The development of venetoclax with HMA has transformed care for elderly adults with AML and opened the door for novel combinations of venetoclax with other nucleoside analogs. Further clinical studies are needed to see if these novel combinations further improve outcomes in AML particularly for patients with high-risk disease.

Published
2022
Full Text
View/download PDF

5. Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity

Author

Amrita Desai, Karamjeet S. Sandhu, Paul B. Koller, Dongyun Yang, Brian J Ball, Sally Mokhtari, Amanda Blackmon, Salman Otoukesh, Shukaib Arslan, Idoroenyi Amanam, Amandeep Salhotra, Ahmed Aribi, Ibrahim Aldoss, Andrew S. Artz, Haris Ali, Anthony S. Stein, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, Michelle Afkhami, and Monzr M. Al Malki

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

6. Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Author

Haris Ali, Dongyun Yang, Sally Mokhtari, Timothy Synold, Idoroenyi Amanam, Andrew S. Artz, Peter T. Curtin, Karamjeet S. Sandhu, Anthony S. Stein, Shukaib Arslan, Salman Otoukesh, Firoozeh Sahebi, Joshua Mansour, Paul B. Koller, Amandeep Salhotra, Ibrahim Aldoss, Vinod A. Pullarkat, Brian J Ball, Stephen J Forman, Guido Marcucci, Monzr M. Al Malki, and Ryotaro Nakamura

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

7. Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Author

Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stephane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian J Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, and Eytan Stein

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

8. Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Author

Janny M. Yao, Hanna Kim, Dongyun Yang, Sally Mokhtari, Salman Otoukesh, Shukaib Arslan, Idoroenyi Amanam, Brian J Ball, Paul B. Koller, Amandeep Salhotra, Ahmed Aribi, Andrew S. Artz, Ibrahim Aldoss, Haris Ali, Anthony S. Stein, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, and Monzr M. Al Malki

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

9. Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Author

Tamer Othman, Ibrahim Aldoss, Ni-Chun Tsai, Hoda Pourhassan, Vaibhav Agrawal, Salman Otoukesh, Idoroenyi Amanam, Dat Ngo, Jason Chen, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S. Sandhu, Shukaib Arslan, Brian J Ball, Forrest M. Stewart, Peter T. Curtin, Andrew S. Artz, David S Snyder, Guido Marcucci, Stephen J Forman, Anthony S. Stein, Ryotaro Nakamura, Vinod A. Pullarkat, Matthew Mei, and Paul B. Koller

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

10. Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Author

Ibrahim Aldoss, Dongyun Yang, Michelle Afkhami, Zhaohui Gu, Sally Mokhtari, Shilpa Shahani, Vaibhav Agrawal, Hoda Pourhassan, Paul B. Koller, Vanina Tomasian, Milhan Telatar, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S. Sandhu, Shukaib Arslan, Brian J Ball, Salman Otoukesh, Idoroenyi Amanam, Andrew S. Artz, Pamela S. Becker, Forrest M. Stewart, Peter T. Curtin, Raju Pillai, Eileen P. Smith, Guido Marcucci, Anthony S. Stein, Stephen J Forman, Ryotaro Nakamura, and Vinod A. Pullarkat

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

11. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification

Author

Joseph GW. McCarter, David Nemirovsky, Christopher A. Famulare, Noushin Farnoud, Abhinita S. Mohanty, Zoe S. Stone-Molloy, Jordan Chervin, Brian J. Ball, Zachary D. Epstein-Peterson, Maria E. Arcila, Aaron J. Stonestrom, Andrew Dunbar, Sheng F. Cai, Jacob L. Glass, Mark B. Geyer, Raajit K. Rampal, Ellin Berman, Omar I. Abdel-Wahab, Eytan M. Stein, Martin S. Tallman, Ross L. Levine, Aaron D. Goldberg, Elli Papaemmanuil, Yanming Zhang, Mikhail Roshal, Andriy Derkach, and Wenbin Xiao

Abstract

Accurate classification and risk stratification is critical for clinical decision making in AML patients. In the newly proposed World Health Organization (WHO) and International Consensus classifications (ICC) of hematolymphoid neoplasms, the presence of myelodysplasia-related (MR) gene mutations is included as one of the diagnostic criteria of AML, myelodysplasia-related (AML-MR), largely based on the assumption that these mutations are specific for AML with an antecedent myelodysplastic syndrome. ICC also prioritizes MR gene mutations over ontogeny (as defined by clinical history). Furthermore, European LeukemiaNet (ELN) 2022 stratifies these MR gene mutations to the adverse-risk group. By thoroughly annotating a cohort of 344 newly diagnosed AML patients treated at Memorial Sloan Kettering Cancer Center (MSKCC), we show that ontogeny assignment based on database registry lacks accuracy. MR gene mutations are frequently seen inde novoAML. Among MR gene mutations, onlyEZH2andSF3B1were associated with an inferior outcome in a univariate analysis. In a multivariate analysis, AML ontogeny had independent prognostic values even after adjusting for age, treatment, allo-transplant and genomic classes or ELN risks. Ontogeny also stratified the outcome of AML with MR gene mutations. Finally,de novoAML with MR gene mutations did not show an adverse outcome. In summary, our study emphasizes the importance of accurate ontogeny designation in clinical studies, demonstrates the independent prognostic value of AML ontogeny and questions the current classification and risk stratification of AML with MR gene mutations.Key pointsBoth ontogeny and genomics show independent prognostic values in AML.The newly proposed myelodysplasia-related gene mutations are neither specific to AML-MRCWHO2016nor predictive for adverse outcomes.Ontogeny stratifies the outcome of AML with myelodysplasia-related gene mutations.

Published
2022
Full Text
View/download PDF

13. Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Author

Vaibhav Agrawal, Hoda Pourhassan, Ni-Chun Tsai, Dat Ngo, Paul B. Koller, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Karamjeet S. Sandhu, Shukaib Arslan, Brian J Ball, Salman Otoukesh, Idoroenyi Amanam, Andrew S. Artz, Pamela S. Becker, Forrest M. Stewart, Eileen P. Smith, Peter T. Curtin, Anthony S. Stein, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, Vinod A. Pullarkat, and Ibrahim Aldoss

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

15. Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

Author

Paul B. Koller, Haoyue Shan, Joycelynne Palmer, Peter T. Curtin, Karamjeet S. Sandhu, Vaibhav Agrawal, Ricardo Spielberger, Joshua Mansour, Amanda Blackmon, Salman Otoukesh, Shukaib Arslan, Idoroenyi Amanam, Eileen P. Smith, Forrest M. Stewart, Brian J Ball, Amandeep Salhotra, Ahmed Aribi, Ibrahim Aldoss, Vinod A. Pullarkat, Anthony S. Stein, Andrew S. Artz, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, Monzr M. Al Malki, David S Snyder, and Haris Ali

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

16. Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Author

Tanya Markary, Tina Nguyen, Ni-Chun Tsai, Shukaib Arslan, Salman Otoukesh, Idoroenyi Amanam, Brian J Ball, Paul B. Koller, Hoda Pourhassan, Vaibhav Agrawal, Len Farol, Karamjeet S. Sandhu, Andrew S. Artz, Amandeep Salhotra, Ibrahim Aldoss, Vinod A. Pullarkat, Haris Ali, Peter T. Curtin, Anthony S. Stein, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, and Monzr M. Al Malki

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

19. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax

Author

Jan Philipp, Bewersdorf, Rory M, Shallis, Andriy, Derkach, Aaron D, Goldberg, Anthony, Stein, Eytan M, Stein, Guido, Marcucci, Amer M, Zeidan, Shai, Shimony, Daniel J, DeAngelo, Richard M, Stone, Ibrahim, Aldoss, Brian J, Ball, and Maximilian, Stahl

Subjects
Proto-Oncogene Proteins p21(ras), Leukemia, Myeloid, Acute, Cancer Research, fms-Like Tyrosine Kinase 3, Oncology, Humans, Antineoplastic Agents, Hematology, Enzyme Inhibitors, Bridged Bicyclo Compounds, Heterocyclic, Isocitrate Dehydrogenase, Retrospective Studies
Abstract

Small molecule inhibitors targeting mutant FLT3, IDH1, and IDH2 as well as venetoclax-based combination therapies have expanded treatment options for patients with acute myeloid leukemia (AML). As the landmark trials leading to the approval of FLT3, IDH1, and IDH2 inhibitors in R/R-AML were conducted prior to the widespread use of venetoclax, it is unclear how these results apply in the current era of venetoclax based therapy frequently being used in the frontline treatment of AML. In this multicenter, retrospective cohort study, we included 53 patients who received FLT3, IDH1 or IDH2 inhibitors after disease progression on venetoclax-based therapy. Among patients treated with targeted agents after venetoclax, the overall response rate (ORR; composite of complete remission [CR]/CR with incomplete count recovery, partial remission, and morphologic leukemia free state) was 17.7 % (n = 9 patients) and median OS of 4.2 months. Eight of 9 patients responding to targeted agents after venetoclax received gilteritinib. None of the patients with RAS pathway mutations responded to targeted agents after venetoclax. Additionally, mutations in TP53 and KRAS were associated with shorter OS among patients treated targeted agents. Our data suggest that response rates to targeted therapies after venetoclax are low and novel therapeutic strategies are warranted.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results